INTRA-CELLULAR THERAPIES INC (ITCI)
US46116X1019 - Common Stock
Noteworthy Thursday Option Activity: ITCI, FSLR, EXAS
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Noteworthy Thursday Option Activity: ULTA, SCCO, ITCI
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Noteworthy Friday Option Activity: BURL, ITCI, CART
Intra-Cellular Therapies misses Q4 estimates (NASDAQ:ITCI)
Intra-Cellular Therapies disappoints with Q4 earnings miss of $2.27 per share and $3.67M in revenue.
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product sales were $462.2 million,...
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Intra-Cellular Therapies Larger Than S&P 500 Component Norwegian Cruise Line Holdings
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
April 19th Options Now Available For Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Intra-Cellular Therapies gains amid repeated takeover speculation
Intra-Cellular Therapies (ITCI) rises as takeover speculation continues, with JPMorgan and Centerview possibly involved.
Intra-Cellular Therapies stock gains amid repeated takeover speculation
Intra-Cellular Therapies (ITCI) rises as takeover speculation continues, with JPMorgan and Centerview possibly involved.
Commit To Buy Intra-Cellular Therapies At $55, Earn 18.6% Annualized Using Options
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA® (lumateperone) in patients...
Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Intra-Cellular Therapies Moves Up In Market Cap Rank, Passing Mohawk Industries
ITCI Makes Bullish Cross Above Critical Moving Average
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
Q3 2023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022 CAPLYTA Q3 2023 net product sales were $125.8...
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Intra-Cellular Therapies is Now Oversold (ITCI)
Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Intra-Cellular Therapies Enters Oversold Territory (ITCI)
Notable Two Hundred Day Moving Average Cross - ITCI
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the 2023 Psych Congress held September 6 - 10, 2023 in Nashville.
Commit To Buy Intra-Cellular Therapies At $45, Earn 9.6% Using Options
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...